Spirapril

This classification denotes an ace inhibitor with the molecular formula C22H30N2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96U2K78I3V, chemically known as 1,4-dithia-7-azaspiro(4,4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8s-(7(r*(r*)),8r*))- but generally known as spirapril, which bears US NIH Compound Identifier 91736. European Medicines Agency schedules Spirapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10620MIG. The term SPIRAPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules spirapril in its Anatomical Therapeutic Chemical (ATC) Classification. SPIRAPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule spirapril under HS 29349990 and SITC 51579. As of Q4 2014, SPIRAPRIL remains the US FDA Preferred Term for this commodity. Spirapril bears US NLM identifiers UMLS ID C0075007 and NCI Concept Code C66560. SMILES: S1C2(SCC1)CC(N(C2)C(=O)C(NC(CCc1ccccc1)C(=O)OCC)C)C(=O)O.